The methylation levels of GHSR and MAL in bladder cancer patients in this validation study were consistent with the earlier findings from the previous preclinical study, showing no significant differences (P = 0.6 and P = 0.3, respectively). This evidence concerns the gene GHSR and urinary bladder carcinoma.